Vitamin B12 Difen-Guyenne B12 Diclofenac Potassium Betamethasone Sodium

Model NO.: vitamin b12


Usage Mode: For external use


State: Solid


Type: Organic Chemicals


Trademark: GUYENNE


Origin: France




Application: Internal Medicine


Suitable for: Elderly, Adult


Shape: Powder


Pharmaceutical Technology: Chemical Synthesis


Specification: GMP/WHO GMP/EURO GMP


HS Code: 3001901000



vitamin b12 Difen-Guyenne B12 Diclofenac Potassiumbetamethasone Sodium Hydroxocobalamine


Product Description



DIFEN-GUYENNE B12 DICLOFENAC POTASSIUMBETAMETHASONE SODIUM

Diclofenac Potassium - Clinical Pharmacology

Pharmacodynamics

Diclofenac Potassium is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of Diclofenac Potassium, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition.

Pharmacokinetics

Absorption

Diclofenac is 100% absorbed after oral administration compared to IV administration as measured by urine recovery. However, due to first-pass metabolism, only about 50% of the absorbed dose is systemically available (see Table 1). In some fasting volunteers, measurable plasma levels are observed within 10 minutes of dosing with Diclofenac Potassium. Peak plasma levels are achieved approximately one hour in fasting normal volunteers, with a range of .33 to 2 hours. Food has no significant effect on the extent of diclofenac absorption. However, there is usually a delay in the onset of absorption and a reduction in peak plasma levels of approximately 30%.

Special Populations



Pediatric

The pharmacokinetics of Diclofenac Potassium has not been investigated in pediatric patients.

Race

Pharmacokinetic differences due to race have not been identified.

Hepatic Insufficiency

Hepatic metabolism accounts for almost 100% of Diclofenac Potassium elimination, so patients with hepatic disease may require reduced doses of Diclofenac Potassium compared to patients with normal hepatic function.

Renal Insufficiency



Diclofenac pharmacokinetics has been investigated in subjects with renal insufficiency. No differences in the pharmacokinetics of diclofenac have been detected in studies of patients with renal impairment. In patients with renal impairment (inulin clearance 60 to 90, 30 to 60, and < 30 mL/min; N = 6 in each group), AUC values and elimination rate were comparable to those in healthy subjects.

Contact us if you need more details on Difen-Guyenne B12. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Dicolfenac Potassium、Betamethasone Sodium Phosphate. If these products fail to match your need, please contact us and we would like to provide relevant information.

Product Categories : Antipyretic & Analgesic Drug